Causaly

We firmly believe in the power of AI to empower R&D productivity across all areas of biomedical research.     By working with global pharma leaders like Novartis, we are helping teams move faster in their drug discovery and development efforts with reliable AI that offers enhanced access to scientific data and ease of implementation.    Learn more about how AI is transforming pharma R&D:    https://lnkd.in/eaTCgAvx    #causaly #novartis #ai #drugdiscovery #lifesciences #research 

Great first day at BioTechX Europe! Visit Causaly at Booth #728 to hear more about our production-grade AI solutions for R&D.

We are excited to present at next week’s BioTechX conference in Basel! Join our Co-Founder and CTO Artur Saudabayev to hear about best practices for production-scale rollouts of AI into R&D Enterprises.

Our CEO Yiannis Kiachopoulos will be moderating a panel on Driving Productivity in R&D with NextPoint Therapeutics, Inc., Be Biopharma, and Affini-T Therapeutics at the #longwoodhealthcareleaders Spring MIT. Reach out if you'll be there and don't miss this session!

Great talk by Berengere Dumotier at #DiscoveryEU24 on the impact of secondary pharmacology data in drug discovery, featuring the Causaly platform.

We're at Oxford Global #DiscoveryEU24! Come meet the Causaly team at Booth #29 to learn how Generative AI can be applied to change and accelerate research workflows. #GenAI #GenAIforlifesciences

📊 *GenAI Adoption = f(Trust, Reproducibility, Verifiability, Breadth & Depth)*🔑 Adoption is ultimately key to whether GenAI leads to value or not. By now most Life Sciences companies are running GenAI PoCs in R&D organizations. The initial setup of these PoCs is often swift, thanks to the capabilities now encapsulated within modern LLMs, which previously required extensive engineering. However, the results from these PoCs can vary significantly. One critical reason is the high standard scientists set for what constitutes credible evidence:   Adoption requires winning the trust of a user, which itself is a function of Transparency, Verifiability and Reproducibility plus being able to answer scientific questions with the requisite depth and breadth they require. While getting to a PoC and some initial excitement is fast, it is a long way to build systems that can create trust with users across a myriad of edge cases that exist in scientific questions. It requires thoughtful system design and robust controls around #LLMs to make them production-ready; At Causaly, this challenge is addressed by our Copilot Operating System, which serves as a command and control center, guiding the operationalization of LLM intelligence within scientific enterprises. Adoption is at the core of how we think about building products and in the end also what determines success or failure of #GenAI initiatives in Enterprises.

Six months ago, we brought together some of the brightest minds in Pharmaceuticals and AI at our inaugural Causaly Connect conference to discuss how AI can catalyze breakthroughs in drug discovery and the development of life-changing therapies. The two-day event was filled with collaborative discussions and insights into how forward-thinking biomedical and AI leaders are transforming healthcare through innovation. 🎥 Missed the event? Watch the sessions on-demand here: https://hubs.la/Q02v7xgs0

A big thank you to all who came to see us at BioIT World! The Causaly team is delighted to have been part of this year's conference, where we showcased our Generative AI solution and discussed the impact of AI in drug discovery. In case you missed us at #BioITWorld, no need to worry! Catch us at Discovery Europe soon 🗓️ #BioITWorld #DrugDiscovery #AI #BioTech

Exploring AI’s Impact on Drug Discovery at Bio-IT World Join us at BioIT World for an insightful session led by Yiannis Kiachopoulos on the transformative role of LLM technologies, Knowledge Graphs, and AI in drug discovery research. Explore how LLMs are revolutionizing R&D productivity and opening new opportunities in drug discovery, marking a pivotal moment in research's current and future landscapes. 📅 Mark your calendar: April 17 at 12:20 PM. #BioITWorld #AIInDrugDiscovery #FutureOfR&D